Xtl Biopharmaceuticals (XTLB) Total Non-Current Liabilities (2012 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Total Non-Current Liabilities of $908000.0 for Q4 2024, up 368.04% on a QoQ basis from $194000.0 in Q2 2022.
Xtl Biopharmaceuticals (XTLB) Total Non-Current Liabilities (2012 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Total Non-Current Liabilities for 8 consecutive years, with $908000.0 the latest figure, recorded in Q4 2024.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $908000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $908000.0 (changed N/A YoY) and the FY2024 annual result came in at $908000.0, changed N/A from the prior year.
- Total Non-Current Liabilities rose to $908000.0 in Q4 2024 per XTLB's latest filing, from $194000.0 in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for XTLB reached as high as $3.6 million in Q3 2021 and fell as low as $194000.0 in Q2 2022.
- A 4-year average of $1.5 million and a median of $1.3 million in 2021 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities soared 744.2% — and 2022, when it tumbled 80.8%.
- Year by year, Total Non-Current Liabilities stood at $2.6 million in 2020, then sank by 51.27% to $1.3 million in 2021, then plunged by 84.9% to $194000.0 in 2022, then surged by 368.04% to $908000.0 in 2024.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $908000.0, $194000.0, and $517000.0 for Q4 2024, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 908,000.00 |
| Jun 30, 2022 | 194,000.00 |
| Mar 31, 2022 | 517,000.00 |
| Dec 31, 2021 | 1.29 Mn |
| Sep 30, 2021 | 3.59 Mn |
| Mar 31, 2021 | 2.69 Mn |
| Dec 31, 2020 | 2.64 Mn |
| Sep 30, 2020 | 1.36 Mn |
| Mar 31, 2020 | 319,000.00 |
| Dec 31, 2017 | 2.67 Mn |
| Sep 30, 2017 | 2.92 Mn |
| Jun 30, 2017 | 4.70 Mn |
| Mar 31, 2017 | 3.75 Mn |
| Jun 30, 2014 | 27,000.00 |
| Mar 31, 2014 | 10,000.00 |
| Dec 31, 2013 | 11,000.00 |
| Dec 31, 2012 | 13,000.00 |